GLAUCIA ITAMARO HEIDEN DOENÇA DE PAGET ÓSSEA ... - UFSC

2744. Goldman L, Ausiello D. Cecil textbook of medicine. 22 ed. Philadelphia: Elsevier 2004.45. Seitz S, Priemel M, Zustin J, Beil FT, Semler J, Minne H, et al. Paget's disease of bone:histologic analysis of 754 patients. J Bone Miner Res. 2009 Jan;24(1):62-9.46. Deyrup AT, Montag AG, Inwards CY, Xu Z, Swee RG, Krishnan Unni K. Sarcomasarising in Paget disease of bone: a clinicopathologic analysis of 70 cases. Archives ofpathology & laboratory medicine. 2007 Jun;131(6):942-6.47. Colucci W, Haghighat A. High-output heart failure 2006 Maio [acesso em 2009 Apr 26];Disponível em: http://www.uptodate.com.48. Kelepouris N. Treatment of Paget's disease of bone. 2007 Abr [acesso em 2008 Jun 15];Disponível em: http://www.uptodate.com.49. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role inclinical practice. Mayo Clinic proceedings. 2008 Sep;83(9):1032-45.50. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, et al. Comparison of a singleinfusion of zoledronic acid with risedronate for Paget's disease. The New England journal ofmedicine. 2005 Sep 1;353(9):898-908.51. Merlotti D, Gennari L, Martini G, Valleggi F, De Paola V, Avanzati A, et al. Comparisonof different intravenous bisphosphonate regimens for Paget's disease of bone. J Bone MinerRes. 2007 Oct;22(10):1510-7.52. Hooper M, Faustino A, Reid IR, Hosking D, Gilchrist NL, Selby P, et al. Randomized,active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solutionfor treatment of Paget's disease. Osteoporos Int. 2009 Jan;20(1):141-50.53. Woo SB, Kalmar JR. Osteonecrosis of the jaws and bisphosphonates. The Alpha omegan.2007;100(4):194-202.